Patients should avoid IGF-1 LR3 without medical clearance if they have blood sugar problems, diabetes risk, cancer history, abnormal growth concerns, cardiovascular disease, kidney or liver issues, active illness, pregnancy, breastfeeding, or current prescription medication use
This maximizes tolerance but significantly extends time to optimal dosing, potentially losing patients to frustration before benefits fully manifest
In a 16-week trial, liraglutide was found to reduce the expressed desire for palatable taste properties, including sweet, fatty, salty, and savory flavors in individuals with obesity (Kadouh et al., 2020)
Pancreatic regulation of glucose homeostasis
Nov 2017;63(4)
Nahapetian, A